SML1973

NVP-AEW541

≥98% (HPLC)

• Sinónimos: 7-[cis-3-(1-Azetidinylmethyl)cyclobutyl]-5-[3-(phenylmethoxy)phenyl]-7H-pyrrolo[2,3-d]-pyrimidin-4-amine, AEW 541, AEW-541, AEW541, cis-7-(3-Aminomethyl-cyclobutyl)-5-(3-benzyloxy-phenyl)-7H-pyrrolo[2,3-d]-pyrimidin-4-ylamine
• Fórmula empírica (notación de Hill): C₂₇H₂₉N₅O
• Número CAS: 475489-16-8
• Peso molecular: 439.55
• NACRES: NA.77
• UNSPSC Code: 12352200

Propiedades

• Nombre del producto: NVP-AEW541, ≥98% (HPLC)
• InChI: 1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)
• InChI key: AECDBHGVIIRMOI-UHFFFAOYSA-N
• SMILES string: NC1=C2C(N([C@H]3C[C@@H](CN4CCC4)C3)C=C2C5=CC=CC(OCC6=CC=CC=C6)=C5)=NC=N1
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C

Descripción

Biochem/physiol Actions

NVP-AEW541 is a reversible, ATP-competitive, orally available insulin-like growth factor-I receptor (IGF-IR, IGF-1R) inhibitor that, despite its equipotency against recombinant kinase domains of insulin receptor (InsR) and IGF-IR in cell-free kinase assays (IC50 = 140 & 150 nM, respectively), exhibits high selectivity toward cellular autophosphorylation of endogenous full-length IGF-1R (IC50 = 86 nM) over InsR (IC50 = 2.3 μM), HER1, PDGFR, c-Kit, and Bcr-Abl p210 (IC50 >5 μM). AEW541 effectively inhibits IGF-IR-mediated signaling and cancer survival (IC50 = 105 nM/MCF-7 soft agar growth, 1.64 μM/NWT-21 proliferation) in cultures and tumor growth in vivo (20 to 50 mg/kg twice daily p.o.; NWT-21 fibrosarcoma & TC-71 musculoskeletal sarcoma xenografts in mice).

Orally available insulin-like growth factor-I receptor inhibitor with in vitro and in vivo efficacy againsgt IGF-IR-mediated signaling and cancer survival.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable